To better characterize the anti-CRC effect of AMTAC-19, we investigated the molecular docking between AMTAC-19 and the crystallographic structures of Mitogen-Activated Protein Kinases (MAPKs). The gene discussed is WNK2; the disease is colorectal carcinoma.